{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:49:35Z","timestamp":1787240975686,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.euo.2022.10.008","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T08:24:48Z","timestamp":1669278288000},"page":"58-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Hyperthermic Mitomycin C in Intermediate-risk Non\u2013muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial"],"prefix":"10.1016","volume":"6","author":[{"given":"Javier C.","family":"Angulo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"\u00c1lvarez-Ossorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"Dom\u00ednguez-Escrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"Moyano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas M.","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"G\u00f3mez-Veiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Unda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Carballido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Carrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s","family":"Fernandez-Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Garc\u00eda de Jal\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Solsona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brant","family":"Inman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Palou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2022.10.008_b0005","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2022.10.008_b0010","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.10.008_b0015","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.juro.2011.07.076","article-title":"A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group","volume":"186","author":"Brausi","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2022.10.008_b0020","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.juro.2014.02.2573","article-title":"Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer","volume":"192","author":"Kamat","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2022.10.008_b0025","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.10.008_b0030","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2022.10.008_b0035","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/bju.12012","article-title":"Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Gu\u00e9rin (BCG): results of an international individual patient data survey (IPDS)","volume":"112","author":"Witjes","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2022.10.008_b0040","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/JU.0000000000001023","article-title":"Cost-effectiveness of maintenance bacillus Calmette-Gu\u00e9rin for intermediate and high risk nonmuscle invasive bladder cancer","volume":"204","author":"Sharma","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2022.10.008_b0045","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/MOU.0000000000000739","article-title":"Treatment options and results of adjuvant treatment in nonmuscle-invasive bladder cancer (NMIBC) during the Bacillus Calmette-Gu\u00e9rin shortage","volume":"30","author":"Fankhauser","year":"2020","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.euo.2022.10.008_b0050","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3109\/02656736.2016.1152632","article-title":"Rationale of hyperthermia for radio(chemo)therapy and immune responses in patients with bladder cancer: biological concepts, clinical data, interdisciplinary treatment decisions and biological tumour imaging","volume":"32","author":"Multhoff","year":"2016","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.euo.2022.10.008_b0055","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/02656736.2016.1155760","article-title":"Chemohyperthermia in non-muscle-invasive bladder cancer: an overview of the literature and recommendations","volume":"32","author":"Liem","year":"2016","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.euo.2022.10.008_b0060","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.3390\/jcm10215105","article-title":"Long-term experience with hyperthermic chemotherapy (HIVEC) using mitomycin-C in patients with non-muscle invasive bladder cancer in Spain","volume":"10","author":"Plata","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.euo.2022.10.008_b0065","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) Prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.10.008_b0070","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association","volume":"148","author":"Barry","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2022.10.008_b0075","first-page":"4189","article-title":"Validity and performance of the Functional Assessment of Cancer Therapy-Bladder (FACT-Bl) among advanced urothelial cancer patients","volume":"27","author":"Degboe","year":"2019","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.euo.2022.10.008_b0080","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrurol.2014.52","article-title":"Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer","volume":"11","author":"Zargar","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2022.10.008_b0085","doi-asserted-by":"crossref","first-page":"94","DOI":"10.21037\/tau.2018.09.09","article-title":"Device-assisted intravesical therapy for non-muscle invasive bladder cancer","volume":"8","author":"Hendricksen","year":"2019","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.euo.2022.10.008_b0090","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3109\/02656736.2016.1142618","article-title":"Recirculant hyperthermic intravesical chemotherapy (HIVEC) in intermediate-high-risk non-muscle-invasive bladder cancer","volume":"32","author":"Sousa","year":"2016","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.euo.2022.10.008_b0095","doi-asserted-by":"crossref","first-page":"e768","DOI":"10.1016\/S1569-9056(19)30563-9","article-title":"HIVEC HR: chemohyperthermia with mitomycin C vs BCG for high-risk non-muscle invasive bladder cancer. Preliminary results from a randomized controlled trial","volume":"18","author":"Gonz\u00e1lez-Padilla","year":"2019","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.euo.2022.10.008_b0100","first-page":"287","article-title":"Outcomes and complications of hyperthermic intravesical chemotherapy using mitomycin C or epirubicin for patients with non-muscle invasive bladder cancer after bacillus Calmette-Gu\u00e9rin treatment failure","volume":"73","author":"Chiancone","year":"2020","journal-title":"Cent European J Urol"},{"key":"10.1016\/j.euo.2022.10.008_b0105","doi-asserted-by":"crossref","first-page":"62.e13","DOI":"10.1016\/j.urolonc.2021.07.019","article-title":"Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer","volume":"40","author":"Pijpers","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2022.10.008_b0110","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1308\/003588414X13946184901001","article-title":"The effects and effectiveness of electromotive drug administration and chemohyperthermia for treating non-muscle invasive bladder cancer","volume":"96","author":"Slater","year":"2014","journal-title":"Ann R Coll Surg Engl"},{"key":"10.1016\/j.euo.2022.10.008_b0115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.purol.2019.11.001","article-title":"Safety of hyperthermic intravesical chemotherapy (HIVEC) for BCG unresponsive non-muscle invasive bladder cancer patients","volume":"30","author":"Marquette","year":"2020","journal-title":"Prog Urol"},{"key":"10.1016\/j.euo.2022.10.008_b0120","doi-asserted-by":"crossref","first-page":"76.e9","DOI":"10.1016\/j.urolonc.2020.07.003","article-title":"Quality of life and adverse events in patients with nonmuscle invasive bladder cancer receiving adjuvant treatment with BCG, MMC, or chemohyperthermia","volume":"39","author":"Gonz\u00e1lez-Padilla","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2022.10.008_b0125","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/21681805.2021.1938664","article-title":"Adverse events of hyperthermic intravesical chemotherapy for non-muscle invasive bladder cancer patients","volume":"55","author":"Thomsen","year":"2021","journal-title":"Scand J Urol"},{"key":"10.1016\/j.euo.2022.10.008_b0130","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.10.008_b0135","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.10.008_b0140","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","article-title":"Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Gu\u00e9rin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer","volume":"69","author":"Arends","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.10.008_b0145","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00345-015-1598-0","article-title":"Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation","volume":"34","author":"Lammers","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2022.10.008_b0150","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.euf.2018.11.005","article-title":"Risk stratification tools and prognostic models in non-muscle-invasive bladder cancer: a critical assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel","volume":"6","author":"Soukup","year":"2020","journal-title":"Eur Urol Focus"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258893112200178X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258893112200178X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:48:50Z","timestamp":1762876130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258893112200178X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S258893112200178X"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2022.10.008","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperthermic Mitomycin C in Intermediate-risk Non\u2013muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2022.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}